AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01013870
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In this Phase II randomized clinical trial of 200 MTBI subjects to evaluate atorvastatin as a neuroprotective agent, subjects will receive either active drug or placebo (1:1 randomization) for 7 days, starting within 24 hours of the brain injury. The dosage for subjects in the treatment group will be weight-based at 1mg/kgm, up to 80 mg, which will be the maximal dose. Subjects will be monitored at 3-4 days after injury by phone, then with follow-up visits at 1 week, 1 month, 3 months.
Trial: NCT02441816
Drug: Aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01934231
Drug: Amoxicillin-Potassium Clavulanate Combination
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The drug is available in two sachets (CVA/AMPC Dry Syrup 0.505 g and CVA/AMPC Dry Syrup 1.01 g). CVA/AMPC Dry Syrup 1.01 g sachet contains 42.9 mg of Potassium Clavulanate and 600 mg of Amoxicillin Hydrate. It is a white to yellowish white powder and has strawberry flavor and it is white to yellowish white suspension when it is suspended before use.
Trial: NCT04960943
Drug: Pyrotinib with or without trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: After enrollment, patients of all the three cohorts were given 400 mg/d oral pyrotinib continuously, every 21 days as a cycle; Cohort 1 and 2 : Patients with gastric cancer or esophageal adenocarcinoma were combined with paclitaxel 80 mg/m2, intravenously, once on the first and eighth day. Cohort 3: Patients with colorectal cancer were given trastuzumab at an initial load dose of 8 mg/kg followed by 6 mg/kg every 3 weeks.
Trial: NCT00289978
Drug: Fingolimod 1.25 mg
DrugBank: Fingolimod (DB08868)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients self-administered fingolimod 1.25 mg capsules orally once daily.
Trial: NCT00289978
Drug: Fingolimod 0.5 mg
RxNorm normalized name: fingolimod 0.5 MG
DrugBank: Fingolimod (DB08868)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients self-administered fingolimod 0.5 mg capsules orally once daily.
Trial: NCT01137565
Drug: AMG 853
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose administration of AMG 853 or placebo in tablet form to adolescent and adult subjects with asthma
Trial: NCT01489826
Drug: Dexanabinol
RxNorm normalized name: Dexanabinol
DrugBank: Dexanabinol (DB06444)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will (initially) be given a slow intravenous (i.v.) infusion of Dexanabinol over 3 hours on Days 1, 8 and 15 of a three weekly (21 day) cycle.
Trial: NCT01084759
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On the day of testosterone injection (i.e. day 1 of each cycle) patients will begin therapy with oral etoposide at a dose of 100 mg/day given in divided doses (one 50 mg etoposide capsule q 12 h) for 14 consecutive days. This dose was selected based on Phase II studies of the combination of oral estramustine and oral etoposide. In these trials, myelosuppression was observed when etoposide was given for 21 days out of a 28 day cycle. Therefore, to minimize toxicity, in this study etoposide will be administered for 14 days of a 28 day cycle.
Trial: NCT01820104
Drug: lansoprazole, 30 mg per day for 6 days
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00215553
Drug: A.1 Lucinactant
DrugBank: Lucinactant (DB04897)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 30 mL aliquots at concentrations of 5, 5, and 10 mg/mL
Trial: NCT00215553
Drug: A.2 Lucinactant
DrugBank: Lucinactant (DB04897)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 30 mL aliquots at a concentration of 10 mg/mL each
Trial: NCT00215553
Drug: A.3 Lucinactant
DrugBank: Lucinactant (DB04897)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 50 mL aliquots at concentrations of 10 and 20 mg/mL
Trial: NCT00215553
Drug: A.4 Lucinactant
DrugBank: Lucinactant (DB04897)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 50 mL aliquots at concentrations of 10 and 20 mg/mL, with bolus re-treatment allowed
Trial: NCT00215553
Drug: B.1 Lucinactant
DrugBank: Lucinactant (DB04897)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 50 mL aliquots at concentrations of 10 and 20 mg/mL
Trial: NCT00215553
Drug: B.2 Lucinactant
DrugBank: Lucinactant (DB04897)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 50 mL aliquots at concentrations of 10 and 20 mg/mL, with bolus re-treatment allowed
Trial: NCT02998099
Drug: Rivipansel
RxNorm normalized name: Rivipansel
DrugBank: Rivipansel (DB12778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of IV rivipansel over 20 minutes.
Trial: NCT00004931
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01060969
Drug: Tadalafil and acetazolamide
RxNorm normalized name: finasteride and tadalafil
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental arm: Tadalafil 20 mg daily + acetazolamide 125 mg BID beginning above 3000 m altitude.
Trial: NCT01060969
Drug: Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active comparator arm (control): acetazolamide 125 mg BID beginning above 3000 m altitude
Trial: NCT04189588
Drug: Cetirizine HCl 10 mg/mL
RxNorm normalized name: cetirizine HCl 10 mg/mL INTRAVEN VIAL (ML)
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of two injectable products: cetirizine HCl 10 mg/mL and diphenhydramine 50 mg/mL, both administered during a 1 to 2-minute period by IV push using a 1 mL syringe
Trial: NCT04189588
Drug: Diphenhydramine 50 mg/mL
RxNorm normalized name: diphenhydrAMINE 50 mg/mL injectable solution
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of two injectable products: cetirizine HCl 10 mg/mL and diphenhydramine 50 mg/mL, both administered during a 1 to 2-minute period by IV push using a 1 mL syringe
Trial: NCT04189588
Drug: anti-CD20 such as Rituximab or Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Compare the number of infusion reactions to treatment with an anti-CD20 such as Rituxan® (Rituximab) or Taxol® (Paclitaxel) after premedication with intravenous (IV) QUZYTTIR™ cetirizine hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion or re-treatment. Re-treatment is defined as re-treatment with Rituxan® (Rituximab) or Paclitaxel after 6 months in patients with persistent infusion reactions while on maintenance or re-treatment.
Trial: NCT02334254
Drug: rivaroxaban and ticagrel therapy
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Antiplatelet therapy are mandatory at least 1 month after bare metal stent implantation, and 6 months after drug-eluting stent implantation.
Trial: NCT02334254
Drug: triple antithrombotic regimen with warfarin, asipirin and clopidogrel
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01634750
Drug: ManNAc
RxNorm normalized name: MANNAC
DrugBank: N-acetylmannosamine (DB12536)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT01122680
Drug: Tiotropium bromide
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: inhalation solution, dose of 1.25 mcg (2 puffs of 0.625 mcg)
Trial: NCT01122680
Drug: tiotropium bromide
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: inhalation solution, dose of 2.5 mcg (2 puffs of 1.25 mcg)
Trial: NCT01122680
Drug: tiotropium bromide
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: inhalation solution, dose of 5 mcg (2 puffs of 2.5 mcg)
Trial: NCT01433965
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide will be taken orally once a day for 21 days continuously in 28 day cycles. The dose of the lenalidomide administered to each patient will be based on the group that the patient is enrolled. The dose cycles will be 21 days of a 28 day cycle.
Trial: NCT00501943
Drug: Avonex (Interferon beta 1a)
RxNorm normalized name: interferon beta-1a Injection [Avonex]
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00501943
Drug: Riluzole
RxNorm normalized name: Riluzole
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00387309
Drug: Methylnaltrexone (MOA-728)
DrugBank: Methylnaltrexone (DB06800)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01235416
Drug: AMG 706
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In each of these 3 planned treatment cohorts, approximately 6 evaluable subjects will be treated with gemcitabine (1000-mg/m2 intravenously over 30 minutes, once weekly starting on day 1, week 1 of cycle 1) and erlotinib (100 mg orally once daily starting on day 1, week 1 of cycle 1)
Trial: NCT00692237
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg daily (3 capsules/day)
Trial: NCT04604366
Drug: misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: it stimulates uterine contractions
Trial: NCT02543645
Drug: Combination of Varlilumab and Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment cycles are 12 weeks each with varlilumab and atezolizumab administered every 3 weeks. During the treatment phase of the study, eligible patients will receive varlilumab for up to 3 cycles (with a 4th cycle possible following discussion with the Medical Monitor). There is no limit on the number of cycles of atezolizumab. Patients may be discontinued from receiving study treatment (atezolizumab or varlilumab) based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.~Phase l Dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg, 1 mg/kg, or 3 mg/kg. The dose of atezolizumab is 1200 mg.
Trial: NCT03779854
Drug: Thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT03779854
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03779854
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03779854
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02302326
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose: metformin (1700 mg / day) for 12 weeks
Trial: NCT03834662
Drug: AVID200
RxNorm normalized name: Tgf-beta 1/3 inhibitor avid200
DrugBank: AVID-200 (DB18454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A TGFβ receptor ectodomain-IgG Fc fusion protein inhibitor of TGFβ
Trial: NCT00000472
Drug: tissue plasminogen activator
RxNorm normalized name: Tissue plasminogen activator
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00683319
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00683319
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01584557
Drug: Tolvaptan or Samsca
RxNorm normalized name: tolvaptan Oral Tablet [Samsca]
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: uncoated tablet, 30mg, once per day, for up to 7 days.
Trial: NCT00346463
Drug: Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00683319
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00737763
Drug: efalizumab
RxNorm normalized name: Efalizumab
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Enrollees randomized to efalizumab will receive the first dose of 0.7mg/kg subcutaneously given at enrollment, and 1.0 mg/kg subcutaneously weekly for 26 weeks self or family-administered after injection training. This is the FDA-approved initial and subsequent doses of efalizumab used for psoriasis treatment
Trial: NCT00442039
Drug: Lithium Carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The starting dose of lithium was 300 mg for patients weighing \< 20 kg
Trial: NCT00442039
Drug: Lithium Carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patients response and tolerability. The starting dose of lithium was 900 mg and the dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patients response and tolerability
Trial: NCT01189812
Drug: Lithium Carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg one time per day for 4 weeks
Trial: NCT00442039
Drug: Lithium Carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The starting dose of lithium was 900 mg and the lithium dose was increased by 300 mg every 3 days, (no more than twice weekly) to maximum tolerated dose based upon the patients response and tolerability.
Trial: NCT01229111
Drug: cediranib maleate
RxNorm normalized name: maleate
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01229111
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01189812
Drug: Citalopram
RxNorm normalized name: Citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will be administered Citalopram 20 mg to to be taken once daily, by mouth for the duration of the double-blind treatment phase (4 weeks)
Trial: NCT00986102
Drug: doripenem
RxNorm normalized name: Doripenem
DrugBank: Doripenem (DB06211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500mg vial by injection every 8 hours for 5 to 14 days
Trial: NCT04572841
Drug: SAR441344
RxNorm normalized name: Immunoglobulin G1 (272-arginine,325-alanine), anti-(human CD40 ligand) (human-mus musculus monoclonal SAR441344 gamma1-chain), disulfide with human-mus musculus monoclonal SAR441344 kappa-chain, dimer
DrugBank: Frexalimab (DB18926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for injection~Route of administration: intravenous or subcutaneous
Trial: NCT02384343
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: An intravenous bolus of dexmedetomidine 30 mcg (7,5 mL) administered at least five minutes after birth, in participants with shivering grade 3 or 4 on a scale described by Crossley and Mahajan.
Trial: NCT04024501
Drug: Verinurad ER8 capsule formulation (fasted)
RxNorm normalized name: Verinurad
DrugBank: Verinurad (DB11873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will receive single-dose treatment of 12 mg verinurad ER8 capsule with 240 mL water, following an overnight fast of at least 10 hours.
Trial: NCT02316132
Drug: Stress
RxNorm normalized name: Stress
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Corticotropin-Releasing Hormone
Trial: NCT02316132
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline 0.9%
Trial: NCT00372515
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On days 1-14 gefitinib will be taken orally daily at either 750, 1000, or 1250mg (depends upon when subject entered trial). If medication is tolerated well, subject will take 500mg daily on days 15-28 of each 28-day cycle. Cycles (higher dose followed by lower dose) will be repeated as long as subject's cancer does not worsen and they do not experience any serious side effects.
Trial: NCT04024501
Drug: Verinurad A-capsule formulation (fasted)
RxNorm normalized name: Verinurad
DrugBank: Verinurad (DB11873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will receive single-dose treatment of 12 mg verinurad A-capsule with 240 mL water, following an overnight fast of at least 10 hours.
Trial: NCT03101670
Drug: filgotinib
RxNorm normalized name: Filgotinib
DrugBank: Filgotinib (DB14845)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: one filgotinib oral tablet q.d.
Trial: NCT04024501
Drug: Verinurad A-capsule formulation (fed)
RxNorm normalized name: Verinurad
DrugBank: Verinurad (DB11873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will receive single dose treatment of 12 mg verinurad A-capsule with 240 mL water, following a high-fat, high-calorie breakfast (after the overnight fast).
Trial: NCT00666575
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 500 mg oral capsule 30 minutes prior to bedtime for 28 days
Trial: NCT02226783
Drug: AZD1722 salt tablet
RxNorm normalized name: Salt solutions
DrugBank: 2-Acetyl-3-[(4-Amino-2-Methyl-5-Pyrimidinyl)Methyl]-4-Methyl-5-(4,6,6-Trihydroxy-3,5-Dioxa-4,6-Diphosphahex-1-Yl)Thiazolium Inner Salt P,P'-Dioxide (DB02410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1722 will be administered as 14 mg (salt tablet). tablet for oral use. Subjects will receive a 14 mg tablet in the morning and evening on Days 1 to 4 (Period 1), Days 7 to 10 (Period 2), and Days 13 to 16 (Period 3).
Trial: NCT02226783
Drug: AZD1722 free base tablet
RxNorm normalized name: Amlodipine free base
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AZD1722 will be given as four 14 mg free-base tablets (56mg) in the morning and evening on Days 1 to 4 (Period 1) and Days 10 to 13 (Period 2).
Trial: NCT02226783
Drug: AZD1722 free base tablet + Omeprazole
RxNorm normalized name: Amlodipine free base
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AZD1722 free base tablet administered 5 to 10 minutes before intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner; omeprazole was administered twice daily from Days -5 to -1 or Days 5 to 9 (depending on assigned treatment period), 1 hour before breakfast and dinner, and from Days 1 to 4 or Days 10 to 13, 1 hour prior to the administration of AZD1722
Trial: NCT04024501
Drug: Verinurad B-capsule formulation (fasted)
DrugBank: Verinurad (DB11873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will receive single-dose treatment of 12 mg verinurad B-capsule with 240 mL water, following an overnight fast of at least 10 hours.
Trial: NCT00063999
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00063999
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00063999
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT01558375
Drug: Water for injection
RxNorm normalized name: WATER FOR INJECTION
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo syringes will contain 0.67ml of sterile water for injection. This will be injecteda daily for 12 weeks.
Trial: NCT01558375
Drug: Anakinra
RxNorm normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anakinra will be supplied in single use pre-filed glass syringes with 27-gauge needles. Anakinra syringe will contain 100mg of anakinra at a volume of 0.67 ml. This will be injected subcutaneously daily for 12 weeks.
Trial: NCT02955550
Drug: rhIL-2
RxNorm normalized name: rhIL-15
DrugBank: Interleukin-15, human recombinant (DB17467)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human recombinant Interleukin-2
Trial: NCT00147537
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Phase 2 Arm A:~Paclitaxel 200 mg/m2, IV over 3 hours up to 6 cycles~Phase 2 Arm B:~Paclitaxel 200 mg/m2, IV over 3 hours up to 6 cycles
Trial: NCT00147537
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phase 2 Arm A:~Carboplatin AUC 6, IV over 15-60 minutes up to 6 cycles~Phase 2 Arm B:~Carboplatin AUC 6, IV over 15-60 minutes up to 6 cycles
Trial: NCT04024501
Drug: Verinurad B-capsule formulation (fed)
DrugBank: Verinurad (DB11873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will receive single dose treatment of 12 mg verinurad B-capsule with 240 mL water, following a high-fat, high-calorie breakfast (after the overnight fast).
Trial: NCT02514967
Drug: Blisibimod
RxNorm normalized name: Blisibimod
DrugBank: Blisibimod (DB12330)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via subcutaneous injection once per week